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Abstract  19 
Choroideremia (CHM) is an x-linked recessive chorioretinal dystrophy, with 30% caused by nonsense 20 
mutations in the CHM gene resulting in an in-frame premature termination codon (PTC).  Nonsense 21 
mediated decay (NMD) is the cell’s natural surveillance mechanism, that detects and destroys PTC 22 
containing transcripts, with UPF1 being the central NMD modulator. NMD efficiency can be variable 23 
amongst individuals with some transcripts escaping destruction, leading to the production of a 24 
truncated non-functional or partially functional protein. Nonsense suppression drugs, such as ataluren, 25 
target these transcripts and read-through the PTC, leading to the production of a full length functional 26 
protein. Patients with higher transcript levels are considered to respond better to these drugs, as more 27 
substrate is available for read-through. Using RT-qPCR, we show that CHM mRNA expression in 28 
blood from nonsense mutation CHM patients is 2.8-fold lower than controls, and varies widely 29 
amongst patients, with 40% variation between those carrying the same UGA mutation (c.715 C>T; 30 
p.[R239*]). These results indicate that although NMD machinery is at work, efficiency is highly 31 
variable and not wholly dependent on mutation position. No significant difference in CHM mRNA 32 
levels was seen between two patients’ fibroblasts and their iPSC-derived RPE. There was no 33 
correlation between CHM mRNA expression and genotype, phenotype or UPF1 transcript levels. 34 
NMD inhibition with caffeine was shown to restore CHM mRNA transcripts to near wildtype levels. 35 
Baseline mRNA levels may provide a prognostic indicator for response to nonsense suppression 36 
therapy, and caffeine may be a useful adjunct to enhance treatment efficacy where indicated.  37 
 38 
 39 
  40 
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Introduction 41 
 42 
Choroideremia (CHM [MIM: 303100]) is an x-linked recessive chorioretinal dystrophy that affects 43 
approximately 1 in 50,000 – 100,000 individuals (1). CHM is characterised by a progressive loss of 44 
vision, starting with night blindness in early childhood, followed by peripheral field loss and 45 
eventually leading to complete blindness in late middle age. CHM is caused by mutations in the CHM 46 
gene (MIM: 300390), located on chromosome Xq21.2, it spans ~150 kb and is composed of 15 exons. 47 
It encodes the ubiquitously expressed 653 amino acid protein, Rab Escort Protein 1 (REP1). REP1 is 48 
involved in intracellular trafficking of vesicles and post-translational modification of Rab-proteins.  49 
 50 
Thirty percent of CHM cases are caused by nonsense mutations, resulting in an in-frame premature 51 
termination codon (PTC)(1). Nonsense mediated mRNA decay (NMD) is the cell’s natural 52 
surveillance mechanism, which detects and destroys PTC containing transcripts. Typically, PTCs 53 
found more than 50-55 nucleotides upstream of the last exon-exon junction are described as being 54 
marked for destruction(2). However, exceptions to this rule have been observed. For example, in T-55 
cell receptor-β, PTCs located within 50 nucleotides of the last exon-exon junction are still degraded 56 
(3).  In the case of the β-globin gene (MIM: 141900), PTCs in close proximity to an AUG codon 57 
evade NMD and trigger translation re-initiation (4). NMD is a complex multifactorial mechanism that 58 
is intrinsically linked to translation. UPF1 is the central NMD factor, it is a RNA dependent ATPase 59 
and an ATP-dependent RNA helicase that is recruited to mRNA and undergoes a cycle of 60 
phosphorylations and dephosphorylations (5). Although NMD is described primarily as a surveillance 61 
mechanism, it also plays an important role in the regulation of normal gene expression and response 62 
to cellular stress (5, 6). 63 
 64 
Some PTC-containing transcripts escape NMD, leading to the expression of a truncated partially 65 
functional or non-functional protein. Nonsense suppression drugs exploit these PTC-containing 66 
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transcripts. They bind to the ribosomal subunit and increase the ability of a near cognate aminoacyl-67 
tRNA to compete with the eukaryotic release factors (eRFs) for binding to the A-site. An amino acid 68 
is added to the growing polypepide chain, effectively allowing ‘read-through’ of the PTC, leading to 69 
production of the full length functional protein (7). We have previously shown that small molecule 70 
drugs, PTC124 and PTC414, restore rep1/REP1 activity in the chmru848 zebrafish model and a patient 71 
CHMY42X fibroblast cell line(8), whereas it was less effective in CHMK248X fibroblasts and induced 72 
pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE)(9).  73 
 74 
It has been suggested that the response to nonsense suppression drugs is greater in patients with 75 
higher baseline transcripts, providing more substrate for drug action, as a result of lower NMD 76 
efficiency (10). NMD efficiency is known to be variable between individuals (11), however it is not 77 
yet fully understood what governs these differences. Linde et al. (2007) found patients with the same 78 
mutation, p.(W1282*), in the cystic fibrosis transmembrane conductance regulator gene (CFTR 79 
[MIM:602421]), had widely variable transcript levels, indicating that NMD is not entirely governed 80 
by PTC position alone(10). 81 
 82 
Baseline mRNA levels may be used as prognostic indicators of treatment outcome and inhibition of 83 
the NMD pathway could be used as an adjunct to boost transcripts for nonsense suppression. Caffeine 84 
has been identified as an NMD inhibitor, due to its inhibitory action on SMG1 kinase activity (12). 85 
Ullrich’s disease (MIM:254090) is a muscular dystrophy, caused by mutations in the collagen VI 86 
genes. Caffeine has been shown to rescue the phenotype in Ullrich’s disease fibroblasts, by increasing 87 
the level of collagen VI α2 mRNA and protein, resulting in efficient integration into the collagen VI 88 
triple helix(13).  Co-administration of the NMD inhibitor NMDI-1 with the nonsense suppression 89 
drug, gentamicin, has been shown to restore full length protein in a model of Hurler syndrome (MIM: 90 
607014)(14).  91 
 92 
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In preparation for a clinical trial with PTC124 (ataluren) for CHM, we examined NMD efficiency in 93 
nonsense mutation CHM patients, determining relative CHM and UPF1 mRNA transcript levels in 94 
blood, fibroblasts and iPSC-derived RPE. We have shown that NMD efficiency is variable in 95 
nonsense mutation CHM patients, and does not correlate with genotype or phenotype. NMD 96 
inhibition increases CHM transcript levels and could be explored as an adjunct for the treatment of 97 
nonsense-mediated diseases.  98 
  99 
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Results 100 
 101 
Variable CHM mRNA expression in patient whole blood 102 
CHM transcript levels in whole blood from 9 CHM male patients with nonsense mutations (mean age 103 
49 ± 15 years) and 6 age and sex-matched healthy controls (mean age 45 ± 15 years) were measured 104 
using RT-qPCR. Patient mutations are shown in Figure 1A and Table 1. CHM transcript levels were 105 
reduced in all patients. Overall, mean CHM mRNA expression in patients was significantly reduced to 106 
36.3 ± 7.3% of control (p=0.002) (Figure 1B). A large variability in transcript levels amongst patients 107 
was seen, ranging from 12.5 to 81.2% of wild type levels. These results indicate that a proportion of 108 
transcripts are escaping NMD. In our cohort, 4 patients have a c.715 C>T; p.(R239*) UGA mutation; 109 
in these patients, CHM transcript levels ranged from 13 to 52.6%. No correlation between CHM 110 
mRNA transcript level and genotype was found (Figure 1C).  111 
 112 
We next analysed the levels of UPF1 in patient blood to determine if there was a correlation between 113 
expression of genes encoding proteins involved in the NMD pathway, and mRNA levels of CHM. 114 
There was no significant difference in UPF1 expression between patients and controls. However, 115 
there was a large variation in UPF1 mRNA expression amongst patients, ranging from 44.3 to 116 
228.1%, compared to wildtype levels (Figure 2). Except for P2 and P7, all other patients had higher 117 
UPF1 expression compared to controls. No correlation between CHM and UPF1 transcript levels was 118 
observed (r=0.07). 119 
 120 
A genotype-phenotype correlation does not exist for choroideremia patients(15). In this population, 121 
the relationship between phenotype (age and fundus autofluorescence [FAF] size) and CHM transcript 122 
levels was investigated, but no statistically significant correlation was found (p=0.21).  Although it is 123 
important to note that in this population, there was also no correlation between age and FAF area (p = 124 
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0.53). So while the multivariate linear model did not suggest statistical significance, it did improve the 125 
correlation over any single factor correlation. Therefore, further investigation in a larger patient cohort 126 
may be needed to determine actual interaction. 127 
 128 
Tissue specific NMD variation 129 
Previous studies have shown that NMD efficiency varies between different murine tissues (16). In 130 
order to investigate tissue specific NMD variation, we have analysed CHM and UPF1 expression in 131 
fibroblasts and iPSC-derived RPE from two unrelated patients; (i) p.(Y42*) and (ii) p.(K258*). CHM 132 
transcript levels in fibroblasts and iPSC-derived RPE for p.(Y42*) were 101 and 92% relative to an 133 
age-matched healthy control and for p.(K258*) were 22.8 and 22.6%, respectively (Figure 3A). UPF1 134 
transcript levels for p.(Y42*) were 142 and 45% and for p.(K258*) were 52.9 and 83.7%, respectively 135 
(Figure 3B). Our results show that the CHM transcript levels in both cell types are similar for each 136 
patient, however UPF1 expression varied considerably amongst the different tissues. CHM mRNA 137 
transcripts in p.(Y42*) are present at wild type levels, indicating that this transcript is escaping NMD.   138 
 139 
NMD inhibition increases CHM mRNA expression in fibroblasts 140 
The effect of caffeine on CHM expression was tested in three independent and unrelated patient 141 
fibroblast cell lines, two with a p.(R270*) mutation and one with a p.(S190*) mutation. Overall, mean 142 
untreated CHM expression was 22.1 ± 1.5% (Figure 4A). Treatment with 10 mM caffeine for four 143 
hours increased CHM transcript levels in all cell lines, to a mean 155 ± 44% of wild type levels, a 7-144 
fold increase (p <0.05) (Figure 4A).  This confirms that active NMD is inhibited, leading to rescue of 145 
PTC-containing transcripts.  146 
To assess whether caffeine intake influenced whole blood CHM mRNA transcript levels, the average 147 
daily caffeine consumption from the FFQ was determined for each CHM patient. There was no 148 
significant difference in daily caffeine consumption between the CHM group (185.4 ± 28.9 mg/day) 149 
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and the age-matched controls (177.1 ± 28.9 mg/day). The average caffeine intake for patients used in 150 
this study (excluding P1, who does not have an NMD-sensitive CHM variant) was 310.8 ± 40 mg/day. 151 
There was no sign of correlation between patient caffeine consumption and CHM mRNA expression 152 
in blood (r= 0.58; p=0.18) (Figure 4B).  153 
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Discussion 154 
 155 
In this study, we have shown that patients with nonsense mutations in the CHM gene have 2.8-fold 156 
lower levels of CHM transcripts compared to controls, indicating that the transcripts are subject to 157 
degradation by NMD, but also a proportion of transcripts are escaping destruction.  All patient 158 
mutations are positioned at least 55 nucleotides upstream of the final exon-exon junction, and 159 
therefore likely substrates of NMD. A wide variation in CHM expression was observed amongst 160 
patients, which did not correlate with genotype, suggesting other factors may be responsible for NMD 161 
efficiency. UPF1 expression, a key NMD facilitator, was also highly variable with no correlation 162 
found with CHM transcript levels. Linde et al. (2007) found NMD efficiency to be variable between 163 
different cells transfected with the same PTC containing genes, suggesting NMD efficiency to be an 164 
inherent characteristic of the cell (17). However, in this study similar levels of CHM transcripts were 165 
found between two different tissue-specific cell types in two unrelated patients. For this to be a useful 166 
patient screening tool for potential response to nonsense suppression, further validation with a greater 167 
number of tissues from more patients would be beneficial.  In contrast, corresponding UPF1 transcript 168 
levels did vary between different cell types. This is consistent with the study by Zetoune et al. (2008) 169 
(16), which showed NMD efficiency varies between different murine tissues and does not correlate 170 
with UPF1 expression or expression of any other genes encoding proteins involved in NMD.  171 
 172 
Our cohort of patients did not show a correlation between disease severity and mRNA expression, 173 
although investigation in a larger patient cohort would increase sensitivity. The role of NMD in the 174 
regulation of normal gene expression is becoming more apparent. Investigation in non-disease 175 
individuals may be valuable to elucidate the causes of variation in NMD efficiency. 176 
 177 
In patient 1, [P1; p.(Y42*)], CHM mRNA levels are comparable to wild type levels in all cell types, 178 
indicating that this transcript is escaping NMD. As this mutation is present near the start of the coding 179 
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sequence, the AUG-proximity effect may be in play here. In a study of 10,000 human tumours, 180 
Lindeboom et al. (2016) found that NMD efficiency is significantly reduced in transcripts with PTCs 181 
located within the first 200 nucleotides of the start codon(18). In P1, the PTC is located 126 182 
nucleotides from the start codon. An AUG-proximal PTC transcript can evade NMD and trigger 183 
translation re-initiation at a downstream codon. Pereira et al., (2015) showed the boundary for 184 
translation re-initiation in the β-globin mRNA is between codons 23 and 25(4). In the CHM transcript, 185 
the next AUG is present at codon 149, which is unlikely to trigger translation re-initiation. However, 186 
NMD efficiency is still lower in AUG-proximal PTC transcripts, even in the absence of a downstream 187 
start codon. An alternative mechanism suggests that the transcript is stabilised by interaction of 188 
cytoplasmic poly(A) binding protein 1 (PABPC1) and the termination complex. In the short open 189 
reading frame of an AUG-proximal PTC transcript, PABPC1 interacting with eukaryotic initiation 190 
factor 4G (eIF4G), is bought into close proximity with the termination complex at the PTC, leading to 191 
an effective termination event, thereby suppressing NMD(19).   192 
 193 
Linde et al. (2007) showed in a group of cystic fibrosis patients with the same p.(W1282*) mutation, 194 
patients had varying levels of baseline CFTR transcripts, and those with higher levels responded better 195 
to the nonsense suppression drug gentamicin(10). A number of other studies have shown that response 196 
to nonsense suppression drugs is highly variable (10, 20, 21). We have previously shown that 197 
treatment with ataluren restores prenylation activity in CHMY42X fibroblasts (8). However, in the study 198 
by Torriano et al. (2018), no significant rescue was observed in CHMK258X fibroblasts and iPSC-199 
derived RPE, which had lower CHM transcript levels (~20%) (9). In preparation for a phase 2 clinical 200 
trial with ataluren for CHM, levels of baseline mRNA may provide a prognostic indicator of response 201 
to treatment. Patients with lower CHM transcript levels may benefit from NMD inhibition to increase 202 
baseline levels, allowing for more effective read-through. Treatment with caffeine restored CHM 203 
mRNA expression to wildtype levels in treated cells. Further clinical studies assessing the direct effect 204 
of caffeine on NMD and resultant CHM mRNA levels following consumption would provide further 205 
evidence of therapeutic benefit. However, caution would be required due to the widespread side 206 
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effects on the body and interactions with many other pathways, and so potentially local delivery 207 
would be more applicable. Keeling et al. (2013) showed in the mucopolysaccharidosis I-Hurler (MPS 208 
I-H) mouse model, co-administration of the NMD specific inhibitor, NMDI-1, together with 209 
gentamicin increased enzyme activity compared to gentamicin alone (14). Recently, an analogue of 210 
NMDI-1 called VG1 has also been developed, using a more efficient process (22). The FDA-211 
approved drug amlexanox, has been shown to have a dual function by inhibiting NMD and promoting 212 
synthesis of full length protein though nonsense suppression (23). 213 
 214 
Together, our results show that NMD efficiencies are highly variable in CHM patients, with no 215 
correlation with genotype or phenotype. Levels of transcripts did not vary between tissues, hence, 216 
measuring baseline mRNA levels in patients with nonsense mutations, if accessible, may act to guide 217 
choice of nonsense suppression therapy with or without NMD inhibitor adjuncts. 218 
 219 
  220 
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Materials and Methods 221 
 222 
Clinical methods 223 
The study protocol adhered to the tenets of the Declaration of Helsinki and received approval from the 224 
NRES Committee London Ethics Committee (REC12/LO/0489) and (REC12/LO/0141). Written, 225 
informed consent was obtained from all participants prior to their inclusion in this study. 226 
 227 
Clinical data was collected from nine male subjects confirmed to have pathogenic variants in the 228 
CHM gene, (Table 1) including age, ethnicity and visual acuity. All retinal imaging was collected as 229 
part of an on-going natural history study of CHM patients for future gene augmentation therapies 230 
tailored to nonsense-mediated disease. Previous work has shown delineation of the central hyper-231 
autofluorescent retinal island area to be the most repeatable metric to measure disease state (24). 232 
Images were acquired using short wavelength (488 nm) autofluorescence on the Heidelberg Spectralis 233 
confocal scanning laser ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany), and area 234 
was measured using the vendor software (Heidelberg Eye Explorer Region Finder Version 2.4.3.0). 235 
 236 
Blood collection and RNA extraction 237 
Whole blood (2.5 ml) was collected from the 9 CHM affected male patients and 6 age and sex 238 
matched healthy controls (Table 1) in PAXgene Blood RNA tubes (QIAGEN). These were incubated 239 
at room temperature for 2 hours to lyse blood cells. Tubes were then transferred to -20 °C until frozen 240 
and subsequently stored at -80 °C, until further processing. Prior to RNA extraction, tubes were 241 
thawed to room temperature. RNA from blood was extracted using the PAXgene Blood RNA kit 242 
(QIAGEN), according to the manufacturer’s instructions. 243 
 244 
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Fibroblast cell culture and dosing 245 
Three patient and one healthy control fibroblast lines were obtained from Coriell Biorepository or 246 
cultured from skin biopsies, as previously described (8) (cell line details are listed in Table 2). Cells 247 
were maintained in Dulbecco’s Modified Eagles Medium (DMEM), high glucose, supplemented with 248 
15% FBS and Penicillin/Streptomycin (ThermoFisher). For cell collection, a T75 confluent flask was 249 
pelleted at 200 g for 5 mins, the pellet was washed in PBS at 200 g for 5 mins at 4˚C twice. All liquid 250 
was removed and the pellet snap frozen in an alcohol/dry ice bath, and stored at -80˚C until further 251 
processing. RNA extraction from cells was carried out using RNeasy Mini Kit (QIAGEN), following 252 
the manufacturer’s instructions. For dosing experiments, fibroblasts were plated in 24 well plates at a 253 
seeding density of 100,000 cells per well for 48 hours. Media was replaced with antibiotic free growth 254 
medium, containing 10 mM caffeine (Sigma). Cells were incubated at 37°C for 4 hours. RNA 255 
extraction was carried out using RNeasy Mini Kit (QIAGEN), following the manufacturer’s 256 
instructions. Three independent experiments were performed. 257 
 258 
Fibroblast reprogramming to iPSCs and generation of RPE 259 
Wild type and CHMY42X fibroblasts were reprogrammed to iPSCs, using integration free episomal 260 
vectors, and subsequently differentiated into RPE, as previously described (25). RT-PCR of RPE-261 
specific marker genes and immunohistochemistry are shown in supplementary data (Figure S1). RNA 262 
extraction was carried out using RNeasy Mini Kit (QIAGEN), following manufacturer’s instructions. 263 
CHMK258X fibroblasts and iPSC-derived RPE, as well as the corresponding RNA, were generated as 264 
previously described (9). 265 
 266 
RT-qPCR 267 
cDNA was synthesised from 500 ng of RNA using the Superscript III First Strand cDNA synthesis kit 268 
(Invitrogen), according to the manufacturer’s instructions. Transcript levels were analysed using 269 
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SYBR Green MasterMix (ThermoFisher) on a StepOne Real-Time PCR system (Applied 270 
Biosystems), under standard cycling conditions. All samples were assayed in triplicate. Primers used 271 
for RT-qPCR are listed in Table 3. GAPDH was used as a reference gene. As the forward CHM 272 
primer overlapped the p.(Y42*) mutation in P1, the 5’ – CGTCAGACATCAGCAGGAGC (forward) 273 
and 5’ – GGATTTGGTGGAGGGGGACA (reverse) primers were used to analyse CHM transcript 274 
levels in P1 blood, fibroblasts and iPSC-derived RPE. 275 
 276 
Patient caffeine consumption  277 
Twenty-five CHM male patients and 25 age and gender matched control subjects were asked to 278 
complete a food frequency questionnaire (FFQ) on their average consumption of various foods and 279 
drinks over the last twelve months. The validated FFQ comprised a list of 147 food items and 280 
participants were asked to indicate their usual consumption from one of nine frequency categories 281 
ranging from “never or less than once per month” to “six or more times per day.”(26). Individuals 282 
would have been excluded if their answers to >10 items had been left blank, but this was not true for 283 
any of the participants.  The amount of caffeine in food and drink items was calculated using a 284 
database with composition values obtained from the USDA Food Composition Databases (Accessed 285 
October 2018). Specifically, using data derived from the USDA National Nutrient Database for 286 
Standard Reference Legacy Release (April 2018) and USDA Branded Food Products Database to 287 
enable average caffeine consumption (mg/day) to be calculated for each patient.  288 
 289 
Statistical Analysis 290 
All data are expressed as mean ± SEM. Differences between control and patient groups were analysed 291 
by Mann-Whitney test. Relationship between CHM and UPF1 transcript levels were analysed by 292 
Pearson’s correlation. To assess the relationship between CHM mRNA expression and clinical 293 
phenotype, multivariate regression analysis for subject age, FAF area and mRNA level was 294 
undertaken (JMP13, Marlow, Buckinghamshire, UK). The effect of caffeine treatment on cells was 295 
15 
 
 
analysed by Kruskal-Wallis analysis, followed by Dunn’s multiple comparisons test. Correlation 296 
between caffeine consumption and CHM mRNA levels was analysed by Pearson’s correlation. A p-297 
value of <0.05 was considered significant.   298 
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Figure legends 389 
Figure 1: CHM mRNA expression is significantly reduced in patients. (A) Schematic of the CHM 390 
gene. Patient mutations used in this study are labelled. (B) Relative CHM mRNA expression in 391 
patients analysed by RT-qPCR. Patients have a 2.8-fold lower expression compared to control 392 
(*p=0.008). (C) Relative CHM mRNA expression in patients, ordered by mutation position. No 393 
correlation was found between CHM mRNA expression and genotype. Data expressed as mean ± 394 
SEM. 395 
Figure 2: UPF1 mRNA expression is widely variable amongst patients (A) Relative UPF1 mRNA 396 
expression in patients analysed by RT-qPCR. No significant difference was found between patients 397 
and controls. (B) Relative UPF1 mRNA expression in patients, ordered by mutation position. No 398 
correlation was found between UPF1 mRNA expression and genotype. Data expressed as mean ± 399 
SEM. 400 
Figure 3: No variation in NMD efficiency was found between cell types. Relative (A) CHM and 401 
(B) UPF1 mRNA expression in CHMY42X (grey) and CHMK258X (white) fibroblasts and iPSC-derived 402 
RPE.  403 
Figure 4: NMD inhibition with caffeine increases CHM mRNA expression. (A) Effect of caffeine 404 
on CHM mRNA expression in unrelated patient fibroblasts (p.[R270*], p.[R270*] and p.[S190*]). 405 
Cells were treated with 10mM caffeine for 4 hrs and mRNA expression analysed by RT-qPCR. 406 
Caffeine significantly increased CHM mRNA expression, compared to untreated cells (p <0.05). Data 407 
expressed as mean ± SEM (n=3). (B) Patients were asked to complete a food questionnaire, and the 408 
average daily caffeine intake was calculated. Correlation between caffeine consumption and relative 409 
CHM mRNA expression was analysed by Pearson’s correlation (r=0.58). No significant correlation 410 
between patient caffeine consumption and CHM mRNA expression (p=0.18) was observed. 411 
 412 
  413 
20 
 
 
Tables 414 
Patient Age cDNA change Amino acid 
change 
Stop 
Introduced  
Exon FAF Area 
(mm2) 
P1 28 c.126 C>G p.(Y42*) UAG 3 1.77 
P2 50 c.698 C>G p.(S233*) UGA 5 0.41 
P3 28 c.715 C>T p.(R239*) UGA 6 22.32 
P4 50 c.715 C>T p.(R239*) UGA 6 19.71 
P5 62 c.715 C>T p.(R239*) UGA 6 19.62 
P6 72 c.715 C>T p.(R239*) UGA 6 2.66 
P7 49 c.799 C>T p.(R267*) UGA 6 18.55 
P8 43 c.877 C>T p.(R293*) UGA 7 10.98 
P9 58 c.1347 C>G p.(Y449*) UAG 10 6.27 
Table 1: Choroideremia male affected patients enrolled in this study.  415 
Fundus autofluorescence (FAF) analysed using the Heidelberg area tool, Heidelberg Engineering. 416 
Variants correspond to RefSeq NM_000390.4 417 
 418 
Age cDNA 
change 
Amino acid change Stop 
Introduced 
Exon Coriell ID 
43  Healthy control   GM23963 
48 c.569 C>G p.(S190*) UGA 5 GM25421 
20 c.808 C>T p.(R270*) UGA 6 GM25383 
61 c.808 C>T p.(R270*) UGA 6 GM25386 
28 c.126 C>G p.(Y42*) UAG 3 Patient skin biopsy 
10 c.772 A>T p.(K258*) UAA 6 Torriano et al. 2018 
Table 2: Fibroblast cell lines used in this study. Cells were obtained from Coriell Institute for 419 
Medical Research or cultured from patient skin biopsies. 420 
21 
 
 
 421 
CHM forward 5’ - AGAAGCTACTATGGAGGAAAC 
CHM reverse 5’ – TTCCTGGTATTCCTTTAGCC 
UPF1 forward 5’ – GCTGTCCCAGTATTAAAAGG 
UPF1 reverse 5’ - CAGTGGTGCTTCAGTTTTAG  
GAPDH forward 5’ - CTTTTGCGTCGCCAG  
GAPDH reverse 5’ - TTGATGGCAACAATATCCAC  
Table 3: RT-qPCR primer sequences 422 
423 
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Abbreviations 424 
CHM, Choroideremia  425 
PTC, Premature termination codon  426 
NMD, Nonsense mediated decay  427 
eRFs, Eukaryotic release factors  428 
iPSC, Induced pluripotent stem cell  429 
RPE, Retinal pigment epithelium  430 
CFTR, Cystic fibrosis transmembrane conductance regulator gene  431 
FAF, Fundus autofluorescence  432 
PABPC1, Poly(A) binding protein 1 433 
eIF4G, Eukaryotic initiation factor 4G  434 
MPS I-H, Mucopolysaccharidosis I-Hurler  435 
SD-OCT, Spectral domain optical coherence tomography  436 
DMEM, Dulbecco’s Modified Eagles Medium  437 
FFQ, Food frequency questionnaire  438 
